Testing may help identify:

  • How your cancer may grow or behave
  • Available treatment options for your unique cancer
  • Information regarding your family's risk for developing certain cancers (depending on the type of test performed)

That’s why you should talk to your doctor about testing as early as possible after your diagnosis. In advanced or recurrent ovarian cancers, certain tests can help determine if you may be eligible for treatment with LYNPARZA.

Know the importance of testing

For HRD in advanced ovarian cancer

Homologous recombination deficiency, or HRD, is an important biomarker of advanced ovarian cancer. An HRD test is a type of genomic test that assesses the DNA profile of your tumor including different mutations, such as mutations in the BRCA1 or BRCA2 genes, and other changes to your DNA.

HRD might be more common than you think

~50% of women with advanced ovarian cancer have tumors that test positive for HRD

Approximately half of these are BRCA mutations, so even if you are BRCA-negative you could still be HRD-positive.

Knowing your HRD status as early as possible after diagnosis can help to determine whether LYNPARZA + bevacizumab may be a first-line maintenance therapy option for you.

Know the importance of testing

For BRCA mutations in advanced or recurrent ovarian cancer

A BRCA mutation is a change or alteration found in the BRCA1 or BRCA2 gene. A BRCA mutation can either be acquired or inherited.

There are 2 types of mutations

Acquired, also known as somatic

  • Develops at some point during a person’s life
  • Not present in every cell
  • Testing is done using a tumor tissue sample from a biopsy

Inherited, also known as germline

  • Passed down from a parent
  • Found in every cell in the body, including tumor cells
  • Testing is done using a blood or saliva sample

Your doctor can perform a test to help determine if you may be eligible for maintenance therapy with LYNPARZA

Ask your doctor about genomic testing